

PCT
JC10 Rec'd PCT/PTO 16 MAY 2005

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/524,691
		Filing Date	February 15, 2005
		First Named Inventor	Yukitsuka KUDO
		Group Art Unit	Not Known
		Examiner Name	Not Known
Total Number of Pages in This Submission		Attorney Docket Number	740630-89
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input type="checkbox"/> Request for Corrected Filing Receipt with Enclosures <input type="checkbox"/> A self-addressed prepaid postcard for acknowledging receipt <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): PTO Form-1449 with 9 reference(s)	
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 for the above identified docket number.	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Individual name	Donald R. Studebaker, Registration No. 32,815 Nixon Peabody LLP 401 9 th Street, N.W. Suite 900 Washington, D.C. 20004-2128		
Signature			
Date	May 16, 2005		



Application No: 10/524,691
Docket No: 740630-89

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	Group Art Unit: Not Known
Yukitsuka KUDO et al.)	
Serial No. 10/524,691)	Examiner: Not Known
Filed: February 15, 2005)	
For: DIAGNOSTIC PROBES AND)	
REMEDIES FOR DISEASES WITH		
ACCUMULATION OF PRION		
PROTEIN, AND STAINS FOR PRIOR		
PROTEIN		

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§1.97 and 1.98.

Pursuant to 37 C.F.R. §1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application, or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. 1.97(b), no fee or statement is required.

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.



Application No: 10/524,691
Docket No: 740630-89

The Commissioner is hereby authorized to charge any fees in connection with this filing which may be required, or credit any overpayment to Deposit Account No. 19-2380 (740630-89).

Respectfully submitted,

By: Donald R. Studebaker
Donald R. Studebaker
Registration No. 32,815

NIXON PEABODY LLP
401 9th Street, N.W.
Suite 900
Washington, D.C. 20004-2128
(202) 585-8000

Date: May 16, 2005



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Application Number				10/524,691	
Filing Date				February 15, 2005	
First Named Inventor				Yukitsuka KUDO et al.	
Art Unit				Not Known	
Examiner Name				Not Known	
Attorney Docket Number				740630-89	
Sheet	1	of	1		
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	1	CAUGHEY et al., "Potent Inhibition of Scrapie-Associated PrP Accumulation by Congo Red", <u>Journal of Neurochemistry</u> , Vol. 59, No. 2, pp. 768-771 (August 1992)			
	2	CAUGHEY et al., "Sulfated Polyanion Inhibition of Scrapie-Associated PrP Accumulation in Cultured Cells", <u>Journal of Virology</u> , Vol. 67, No. 2, pp 643-650, (February 1993)			
	3	CAUGHEY et al., "Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines", <u>Proceedings of the National Academy of Sciences of the United States of America</u> , Vol. 95, pp. 12117-12122 (October 1998)			
	4	DOH-URA et al., "Brain injury does not modify transmissible spongiform encephalopathy caused by intraperitoneal inoculation with Fukuoka-1 strain" <u>Journal of General Virology</u> , Vol. 80, pp. 1551-1556 (1999)			
	5	RACE et al. "Analyses of Frequency of Infection, Specific Infectivity, and Prion Protein Biosynthesis in Scrapie-Infected Neuroblastoma Cell Clones" <u>Journal of Virology</u> , Vol. 62, No. 8, pp. 2845-2849 (August 1988)			
	6	DOH-URA et al., "Lysosomotropic Agents and Cysteine Protease Inhibitors Inhibit Scrapie-Associated Prion Protein Accumulation", <u>Journal of Virology</u> , Vol. 74, No. 10, pp. 4894-4897 (May 2000)			
	7	DOH-URA et al., "Enhanced CD9 Expression in the Mouse and Human Brains Infected with Transmissible Spongiform Encephalopathies" <u>Journal of Neuropathology and Experimental Neurology</u> , Vol. 59, No. 9, pp. 774-785 (September 2000)			
	8	KORTH et al., "Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease", <u>Proceedings of the National Academy of Sciences</u> , Vol. 98, No. 17, pp. 9836-9841 (August 14, 2001)			
	9	SUPATTAPONE et al., "Branched Polyamines Cure Prion-Infected Neuroblastoma Cells" <u>Journal of Virology</u> , Vol. 75, No. 7, pp. 3453-3461 (April 2001)			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.